FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
- DOI
- 10.1038/s41591-026-04522-3
- Published
- 2026 Aug
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-026-04522-3,
title = {FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.},
author = {Cohen AD and Richter J and Trudel S and Lesokhin A and Laubach JP and Thomas SK and Harrison SJ and Costa LJ and Spencer A and Fonseca R and Forsberg PA and Berdeja JG and Kaedbey R and Bahlis NJ and Rodriguez-Otero P and Mateos MV and Tyagi T and Samineni D and Liu W and Nakamura R and Choeurng V and Wong C and Cooper J and Krishnan A},
year = {2026},
journal = {Nature medicine},
doi = {10.1038/s41591-026-04522-3},
url = {https://doi.org/10.1038/s41591-026-04522-3}
}RIS
TY - JOUR TI - FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. AU - Cohen AD AU - Richter J AU - Trudel S AU - Lesokhin A AU - Laubach JP AU - Thomas SK AU - Harrison SJ AU - Costa LJ AU - Spencer A AU - Fonseca R AU - Forsberg PA AU - Berdeja JG AU - Kaedbey R AU - Bahlis NJ AU - Rodriguez-Otero P AU - Mateos MV AU - Tyagi T AU - Samineni D AU - Liu W AU - Nakamura R AU - Choeurng V AU - Wong C AU - Cooper J AU - Krishnan A PY - 2026 JO - Nature medicine DO - 10.1038/s41591-026-04522-3 UR - https://doi.org/10.1038/s41591-026-04522-3 ER -
APA
AD, C., J, R., S, T., A, L., JP, L., SK, T., SJ, H., LJ, C., A, S., R, F., PA, F., JG, B., R, K., NJ, B., P, R., MV, M., T, T., D, S., W, L., R, N., V, C., C, W., J, C., & A, K. (2026). FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04522-3
Source records
- pubmed · retrieved 2026-09-25T11:49:27.046Z